An Open Label Continuation Study of the Oral AKT Inhibitor GSK2110183 in Subjects With Solid Tumors and Hematologic Malignancies.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Afuresertib (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2014 Planned End Date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 25 Jul 2014 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.